NCCN 2019 Oncology Fellows Program: New Horizons in Quality Cancer Care™

Orlando, FL US
March 24, 2019

The purpose of this well-regarded program is to educate future oncology leaders about the application of the NCCN Guidelines® to the management of significant cancer types and supportive care issues. The NCCN Oncology Fellows Program has established itself as a premier career-enhancing event for oncology fellows across the United States.

Target Audience

This educational program is designed to meet the educational needs of second- and third-year medical, surgical, and radiation oncology fellows.

Learning Objectives

Following this program, participants should be able to:

Multidisciplinary Approach to Treatment of Locally Advanced (Stage III) Non-Small Cell Lung Cancer (NSCLC)
•    Recognize the need for multidisciplinary review before starting treatment for patients with stage III NSCLC.
•    Describe the role of durvalumab in patients with unresectable stage III NSCLC.
•    Educate patients and staff about the potential for adverse events in patients receiving immunotherapy such as durvalumab.

New Therapeutic Approaches for Treating Thyroid Cancer
•    Discuss the uses and limitations of molecular markers for thyroid cancer diagnosis and treatment.
•    List common treatment modalities for thyroid cancer and describe circumstances in which their use would be appropriate.
•    Describe emerging data supporting new treatment options for advanced thyroid cancers.

Pathologic Evaluation of Cervical and Uterine Malignancies – Implications for Treatment
•    Identify histopathologic risk factors that may impact treatment decisions for cervical and endometrial cancers.
•    Discuss the emerging role of molecular pathology in gynecologic malignancies.
•    Utilize the NCCN Guidelines for a standardized approach to the pathologic evaluation of cervical and endometrial cancers.

Treatment Considerations in Adolescent and Young Adults with Cancer
•    Identify challenges associated with cancer treatment and management in the AYA population.
•    Develop strategies to address the unique supportive care needs of AYA patients with cancer.
•    Discuss late effects of cancer treatment, including impact on fertility, for AYA cancer survivors and screening/management recommendations.

Use of Direct Oral Anticoagulants for Treatment Venous Thromboembolism (VTE) in Cancer Patients
•    Describe the specific indication for which each of the “new” direct oral anticoagulants are recommended in the NCCN Guidelines for treatment of VTE in patients with cancer.
•    Describe the recommended workup for determining whether a patient is an appropriate candidate for anticoagulation using direct oral agent, and describe considerations for choosing among these agents.
•    List key points to cover in discussions with patients regarding their anticoagulation options and duration of treatment for cancer-associated VTE.

Wellness and Burnout – Strategies for the Practicing Oncologist and Oncology Institutions
•    Recognize contributing causes to and symptoms of burnout among oncologists.
•    List self-care strategies that may be used by oncologists to prevent and/or alleviate burnout.
•    Describe steps that the health care organization/institution can take to prevent and reduce burnout among oncologists.

Additional information

This activity is supported by an educational grant from

  • AstraZeneca
  • Genentech
  • Pfizer


Course summary
Course opens: 
Course expires: 
Event starts: 
03/24/2019 - 7:15am EDT
Event ends: 
03/24/2019 - 11:30am EDT
The Rosen Shingle Creek
9939 Universal Boulevard
Orlando, FL 32819
United States

NCCN Medical Education Disclosure Policy

It is the policy of NCCN that every 12 months, all faculty, moderators, activity planners and all internal planning staff participating in NCCN continuing education activities are expected to disclose any financial relationships with a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support. In addition, all faculty presentations have been reviewed for adherence to the ACCME’s Standards for Commercial Support (the provider develops activities/educational interventions independent of commercial interests [SCS 1, 2 and 6] by experts on the topics). Full disclosure of faculty relationships will be made prior to the activity.

Per the ACCME Standards for Commercial Support, individuals who do not disclose relevant financial relationships will be disqualified from involvement in the CE activity as a content developer, planner, or presenter. A complete list of individuals’ relationships with external entities is available upon request.


NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.

NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing